Insider Transactions in Q1 2025 at Supernus Pharmaceuticals, Inc. (SUPN)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 07
2025
|
Jack A. Khattar President, CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
18,581
-1.87%
|
$724,659
$39.11 P/Share
|
|
Mar 07
2025
|
Jack A. Khattar President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
38,640
+3.75%
|
-
|
|
Mar 07
2025
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
SELL
Payment of exercise price or tax liability
|
Direct |
1,356
-8.21%
|
$52,884
$39.11 P/Share
|
|
Mar 07
2025
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Exercise of conversion of derivative security
|
Direct |
2,625
+13.72%
|
-
|
|
Mar 05
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,485
-3.61%
|
$49,005
$33.05 P/Share
|
|
Mar 05
2025
|
Timothy C Dec Senior Vice-President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,193
-8.11%
|
$105,369
$33.05 P/Share
|
|
Mar 05
2025
|
Jonathan Rubin SVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,468
-4.61%
|
$48,444
$33.05 P/Share
|
|
Mar 05
2025
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
SELL
Payment of exercise price or tax liability
|
Direct |
1,892
-4.15%
|
$62,436
$33.05 P/Share
|
|
Feb 26
2025
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
SELL
Payment of exercise price or tax liability
|
Direct |
2,885
-8.67%
|
$112,515
$39.48 P/Share
|
|
Feb 26
2025
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Exercise of conversion of derivative security
|
Direct |
5,760
+14.69%
|
-
|
|
Feb 23
2025
|
Jonathan Rubin SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,250
+10.12%
|
-
|
|
Feb 23
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Grant, award, or other acquisition
|
Direct |
1,250
+8.1%
|
-
|
|
Feb 23
2025
|
Timothy C Dec Senior Vice-President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+15.07%
|
-
|
|
Feb 23
2025
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Grant, award, or other acquisition
|
Direct |
1,875
+12.69%
|
-
|
|
Feb 22
2025
|
Jonathan Rubin SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+9.64%
|
-
|
|
Feb 22
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+7.42%
|
-
|
|
Feb 22
2025
|
Timothy C Dec Senior Vice-President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
3,500
+13.03%
|
-
|
|
Feb 22
2025
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+8.66%
|
-
|
|
Feb 22
2025
|
Frederick M. Hudson Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,369
+9.08%
|
-
|
|
Feb 22
2025
|
Georges Gemayel Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,369
+22.32%
|
-
|
|
Feb 22
2025
|
Charles W Newhall Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,369
+3.81%
|
-
|
|
Feb 22
2025
|
Bethany Sensenig Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,369
+50.0%
|
-
|
|
Feb 22
2025
|
Carrolee Barlow Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,369
+19.22%
|
-
|
|
Feb 21
2025
|
Jonathan Rubin SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
927
-10.56%
|
$36,153
$39.15 P/Share
|
|
Feb 21
2025
|
Jonathan Rubin SVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,875
+17.6%
|
-
|
|
Feb 21
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
860
-7.29%
|
$33,540
$39.15 P/Share
|
|
Feb 21
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,650
+12.27%
|
-
|
|
Feb 21
2025
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
SELL
Payment of exercise price or tax liability
|
Direct |
552
-5.76%
|
$21,528
$39.15 P/Share
|
|
Feb 21
2025
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Exercise of conversion of derivative security
|
Direct |
1,125
+10.51%
|
-
|
|
Feb 04
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Open market or private sale
|
Direct |
9,477
-48.29%
|
$369,603
$39.7 P/Share
|
|
Feb 04
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,477
+32.56%
|
$274,833
$29.61 P/Share
|
|
Jan 28
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Open market or private sale
|
Direct |
700
-6.45%
|
$27,300
$39.62 P/Share
|
|
Jan 28
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
700
+6.06%
|
$20,300
$29.61 P/Share
|
|
Jan 27
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Open market or private sale
|
Direct |
2,573
-20.22%
|
$100,347
$39.62 P/Share
|
|
Jan 27
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,573
+16.82%
|
$74,617
$29.61 P/Share
|
|
Jan 22
2025
|
Frederick M. Hudson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+29.24%
|
$180,000
$9.13 P/Share
|